ANALYSIS: Abbott/St Jude Merger Would Make Sense But Vascular Closure Potential Snag

Media reports of a potential $25bn bid by Abbott Laboratories for St Jude Medical, Inc., may have been promptly knocked down by Abbott, but that has not stopped shares of the cardiology firm rallying in the wake of the rumors.

Citing sources familiar with the matter, The Financial Times reported in early hours of August 27 that the Illinois-based drug...